To address this question, two xenograft tumor models expressing EGFR were selected for characterization of matriptase and uPA protease activity: (1) H292, derived from a mucoepidermoid lung carcinoma; and (2) FaDu, derived from a head and neck carcinoma. Here, EGFR is linked to pulmonary mucoepidermoid carcinoma.